Ref-1 [also designated as human apurinic/apyrimidinic endonuclease (APE, HAP1, and APEX)], a multifunctional protein, has a DNA repair domain in its COOH terminus, which is highly homologous to the sequence of Escherichia coli exonuclease III (36) , and a redox regulation domain in its NH 2 terminus, which is involved in the regulation of the DNA binding activity of a group of nuclear factors including activator protein-1 (AP-1), NF-B, p53, hypoxia-inducible factor (HIF)-1␣, HIF-like factor, and others via redox modification of a cysteine residue in the target protein (12, 19, 23, 26, 46, 47) . The redox activity of Ref-1 is regulated by chemical reduction and oxidation in vitro (8, 46, 47) and may involve Cys-65 and Cys-93 in the NH 2 -terminal region of the protein (43) . In cultured cells, Ref-1 serves as an intermediary between thioredoxin and AP-1 in response to oxidant stress induced by PMA (19) or ionizing radiation (44) and mediates AP-1 activation by heat shock (8) . However, whether Ref-1 is involved in redox regulation of cell proliferation either in SMCs or in other types of cells is currently unknown.
Previous studies (27, 34, 37, 39) from our lab and others have shown that PDGF can activate NAD(P)H oxidase in SMCs to produce O 2 Ϫ ⅐. This growth factorinduced NAD(P)H oxidase-dependent reactive oxygen species (ROS) generation leads to activation of transcription factors such as AP-1 and, consequently, cell proliferation (14, 22, 34, 39) . Although Ref-1 has been reported to be elevated in some cancers such as prostate, ovarian, and cervical cancer (25, 30, 48) , and to be involved in inhibition of apoptosis (6) , a potential role of Ref-1 in SMC proliferation has not been examined. Accordingly, this study was undertaken to test the role of Ref-1 in SMC mitogenesis and cell cycle progression. PDGF-BB (composed of the homodimer of B-polypeptide chain), which binds to both the ␣-and ␤-subunits of the PDGF receptor and therefore has the most potent mitogenic activity among the three isoforms (17) , was used to stimulate SMC growth.
MATERIALS AND METHODS
Cell culture. SMCs were isolated from the thoracic aortas of 250-to 300-g male Sprague-Dawley rats by enzymatic digestion, as described previously (9, 27) . Our protocol was approved by the Animal Care and Use Committee at the University of Iowa and conformed to American Physiological Society "Guiding Principles in the Care and Use of Laboratory Animals." Cells were grown in DMEM (low glucose) supplemented with 10% FCS, HEPES (10 mM), penicillin (100 U/ml), and streptomycin (100 g/ml) in a humidified 10% CO 2 atmosphere at 37°C. Culture medium was changed every 3 days. All experiments were performed on cells between passages 3 and 15. Transfection with oligodeoxynucleotides. Transfection was carried out by using an Effectene transfection reagent kit (Qiagen, Valencia, CA) following the manufacturer's supplied protocol. In brief, 1.35 or 2.7 l of 100 M of AODN or control ODN were diluted with DNA-condensation buffer (buffer EC) to 90 l, followed by mixing with 4.8 l of Enhancer. After incubation at room temperature for 5 min, 15 l of Effectene transfection reagent were added to the DNA-Enhancer mixture and incubated at room temperature for 10 min. The mixture was then diluted with serumfree DMEM and applied to cells. SMCs (50-60% confluent) were treated with 0.012 or 0.024 M of AODN or control ODN in 11 ml of serum-free DMEM per 100-mm dish, or with 0.012 or 0.024 M of AODN or ODN in 1 ml of serum-free DMEM per well of a 24-well plate, for 24 h. The incubation media were replaced by serum-free DMEM with or without 10 ng/ml recombinant human PDGF-BB (Intergen, Purchase, NY) as indicated in each experimental protocol.
[ 3 H]thymidine incorporation. Cellular DNA synthesis was examined as described previously (5) . In brief, cells were grown to 50% confluence in 24-well plates, treated with 0.012 M AODN or control ODN in serum-free DMEM for 24 h, and then incubated with serum-free DMEM with or without PDGF-BB (10 ng/ml) for an additional 9 h. One Ci/ml [ 3 H]thymidine (Amersham Pharmacia Biotech, Piscataway, NJ) was added, and the incubation was continued for 2 h. After the medium was removed, the attached cells were washed with cold PBS, incubated in 20% trichloroacetic acid for 30 min, washed, and then incubated in 0.25 M NaOH for 12 h. The cells were then lysed by vortexing and analyzed for radioactivity by liquid scintillation counting. The number of attached cells in each well was counted by using a Coulter particle counter (Beckman Coulter) in a parallel culture. The incorporated radioactivity [counts per minute (cpm)] per cell was calculated, and results were expressed as the ratio of PDGF-BB treated sample to control. Experiments were performed three times in triplicate 24-well plates. (10) were generated by the University of Iowa Gene Transfer Vector Core. The particle titer of Adref-1 stock was 1.2 ϫ 10 12 DNA particles/ml, and the functional titer was 4 ϫ 10 10 plaque-forming units (pfu)/ml. The titer of adenoviral constructs containing ␤-galactosidase (AdlacZ, control vector) was 1.2 ϫ 10 10 pfu/ml. Subconfluent SMCs in 100-mm dishes were incubated with Adref-1 or AdlacZ at indicated MOI in 6 ml of serum-free DMEM for 24 h. Cells were then incubated with serum-free DMEM for 12 h, followed by PDGF-BB treatment if used.
Flow cytometric analysis of bromodeoxyuridine-labeled cells. Progression of the cell cycle was monitored by flow cytometric analysis of bromodeoxyuridine (BrdU) incorporation vs. DNA content following a previously published procedure (13) . Briefly, after 24 h of treatments with AODN or control ODN in serum-free medium, SMCs grown in 100-mm dishes were treated with or without PDGF-BB (10 ng/ml) for 6, 9, or 12 h. Cells were pulse-labeled with 10 M of BrdU (Sigma, St. Louis, MO) for 30 min. The attached cells were collected by trypsinization and fixed with cold 70% ethanol immediately after the labeling. Fixed cells were treated with HCl/pepsin, and indirect immunostaining was performed by using anti-BrdU monoclonal antibody (Becton Dickinson Immunocytometry Systems, San Jose, CA). Nuclei were then treated with FITC-conjugated anti-BrdU mouse monoclonal antibody (Becton Dickinson Immunocytometry Systems) and counterstained with propidium iodide (Sigma, St. Louis, MO). Fluorescence-activated cell sorting (FACS) analysis was performed by using a FACScan (Becton Dickinson). Twenty thousand cells were measured for each sample and data were analyzed by using CellQuest software. For BrdU pulse-chase experiments (18) , cells were infected with 250 multiplicity of infection (MOI) of Adref-1 or AdlacZ in serumfree medium for 24 h. Infected cells were then cultured in DMEM containing 10% FCS for 24 h. Cells were pulse labeled with BrdU for 30 min, chased in BrdU-free DMEM containing 10% FCS for an additional 12 h and assayed for cell cycle phase distribution by flow cytometry.
EMSA for DNA protein binding. For preparation of nuclear extracts, cells were resuspended in 0.05 M potassium phosphate buffer containing 1% NP-40 (Armesco, Solon, Ohio), 1 mM PMSF (Armesco), 1.5 mM pepstatin (Roche Molecular Biochemicals), and 8.4 mM leupeptin (Roche Molecular Biochemicals) and incubated on ice for 30 min. The cells were then lysed by passing through a 25.5-gauge needle. The nuclei were pelleted by centrifugation at 4°C two times for 1 min at 2,000 g, and the supernatants were removed after each spin. The pelleted nuclei were resuspended in ice-cold buffer C (in mM: 20 HEPES, 0.42 NaCl, 1.5 MgCl2, 0.2 EDTA, 1 PMSF, 1.5 pepstatin, and 8.4 leupeptin and 25% glycerol), and placed on ice for 40 min. The suspensions were centrifuged at 16,400 g for 6 min, and the supernatants were collected and diluted with ice-cold buffer D (in mM: 20 HEPES, 0.1 KCl, 0.2 EDTA, 1 PMSF, 1.5 pepstatin, and 8.4 leupeptin and 20% glycerol). The nuclear protein concentration was determined before EMSA was performed.
For EMSA (20) , 1-10 g of nuclear proteins were incubated in a total volume of 20 l consisting of 1 g of poly-(dIdC), 1ϫ gel shift buffer, and 5 l of 32 P-labeled doublestranded ODN (ϳ100,000 cpm) containing a consensus AP-1 binding sequence (underlined) (5Ј-AGCTTGTGAGTCAGC-CGGATC-3Ј) on ice for 45 min. The 5Ј overhangs of doublestranded ODN (100 ng) containing the AP-1 cis-element were labeled by a Klenow fill-in reaction in the presence of 20 Ci [ 32 P]dCTP (New England Nuclear Life Science Products, Boston, MA). For DTT recovery experiments, nuclear extracts were incubated with 1ϫ gel shift buffer and 0.5 mM DTT on ice for 45 min. Then, 1 g of poly(dIdC) and 5 l of 32 P-labeled double-stranded ODN (ϳ100,000 cpm) containing a consensus AP-1 binding sequence were added to the above mixture and incubated for another 45 min. For gel supershifts, 4 g of nuclear protein derived from PDGF-BBtreated cells were incubated with 6 g of anti-Jun-B antibody at room temperature for 25 min and then 1 g of poly(dIdC), 1ϫ gel shift buffer, and 5 l of 32 P-labeled double-stranded ODN containing a consensus AP-1 binding sequence were added to above solution and incubated for another 30 min at room temperature. Samples were electrophoresed on 5% nondenaturing polyacrylamide gel and exposed to Biomax MR film at Ϫ80°C overnight.
For experiments designed to test the effects of immunodepletion of Ref-1 from nuclear extracts, subconfluent SMCs were growth arrested in serum-free DMEM for 48 h and then treated with 10 ng/ml of PDGF-BB for 3 h. After nuclear extracts were collected, 50 l (45-50 g) of control or PDGF-treated nuclear extracts were incubated with 0.32 g of nonimmune rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) or anti-Ref-1 antibody (Santa Cruz Biotechnology), and 35 l of protein A-agarose (Santa Cruz Biotechnology), by shaking at 4°C for 2 h. After centrifugation, the supernatants were collected, and the protein concentration was determined. Equal amounts of protein from each sample were subjected to EMSA.
Western blot analysis. Cells were harvested by scraping. Cell pellets were resuspended in 0.05 M potassium phosphate buffer and lysed by sonicating on ice with four bursts of 30 s each by using a Vibra Cell Sonicator (Sonics and Materials). Equal amounts of protein from the cell lysates were denatured with protein solubilization buffer at 100°C for 5 min and electrophoresed in a 12.5% SDS-polyacrylamide running gel and a 5% stacking gel. The protein was then electrotransferred onto a nitrocellulose membrane. After being blocked in 5% nonfat milk at room temperature for 1 h, the blot was washed and incubated with antibody against Ref-1 (1:250) and Jun-B (1:200) (Santa Cruz Biotechnology) at 4°C overnight. The blot was then washed and incubated with horseradish peroxidase-conjugated antibody against IgG (Boehringer-Mannheim, Indianapolis, IN) at room temperature for 1 h. The washed blot was then treated with enhanced chemiluminescence solution and exposed to Biomax MR film. Quantifications of optical densities of the bands were performed by using AlphaImager 2200 v5.5 (Alpha Innotech). The protein loading of all gels was verified by Coomassie blue staining.
Statistical analyses. Data are presented as means Ϯ SD from three independent experiments. Differences among mean values of multiple groups were analyzed by using SigmaStat 2.0 for Windows. ANOVA-Tukey was used to determine the significance of differences at P Ͻ 0.05.
RESULTS
To investigate whether rat SMCs express Ref-1 protein, and whether PDGF-BB affects Ref-1 protein levels, SMCs were growth arrested with serum-free medium for 24 h followed by treatment with or without 10 ng/ml of PDGF-BB in serum-free medium for 1, 3, 6, 12, 24, or 48 h. Cellular lysates were collected and subjected to Western blotting. Results obtained after incubations of 1 h (Fig. 1A, lane 1 (Fig. 3) . Cells stimulated with PDGF-BB alone were used for comparison. Cells were then pulse labeled with BrdU and harvested for FACS analysis immediately at the end of the labeling period. Representative results presented in Fig. 3A showed that 76% of the cells were in G 0 /G 1 and only 5% cells were in S in serum-starved control cells. Twelve hours after PDGF-BB-stimulation, 57% of the cells incorporated BrdU, suggesting that majority of the cells entered S during this time interval. However, PDGF-stimulated entry into S was significantly inhib-
In these experiments, neither the transfection vehicle nor the control ODN (sense, scrambled, or mismatch) had a significant inhibitory effect on progression from G 0 /G 1 to S. Quantification of three independent experiments (Fig. 3B) shows a statistically significant inhibitory effect of ref-1 AODN on PDGF-BB-induced S entry compared with PDGF-BB alone or treatment with sense ODN. A time course experiment showed that S entry was delayed by ref- 1  AODN (Fig. 3C) . We observed no sub-G 1 (34), we used anti-Jun-B antibody to supershift AP-1 complexes to confirm that the DNA binding was specifically due to AP-1 (Fig. 5B, lane 1) . The arrow indicates the supershifted AP-1 complex. Then, subconfluent SMCs were incubated with ODN in serum-free medium for 24 h and treated with PDGF-BB for 3 h. Preincubation with Ref-1 AODN (Fig. 5, C and D, lanes 4) (Fig. 6) . As a control, nonimmune rabbit IgG was applied. PDGF-BB-induced AP-1 DNA binding was markedly decreased by treatment with anti-Ref-1 rabbit IgG compared with nonimmune IgG or PDGF-BB alone (Fig. 6, lanes 2, 4, and 6) . After immunoprecipitation of nuclear extracts with anti-Ref-1 rab- bit IgG, Western blotting of supernatants demonstrated that Jun-B levels were not decreased by the immunoprecipitation process (data not shown), suggesting that the decreased AP-1 DNA binding was due to loss of Ref-1 protein in the nuclear extracts. Furthermore, preincubation of PDGF-BB-treated nuclear extracts from which Ref-1 had been immunodepleted in the presence of 0.5 mM DTT restored the AP-1 DNA binding activity (Fig. 6, lane 6 vs. lane 8 AP-1, an inducible transcription factor that recognizes a palindromic sequence (5Ј-TGACTCA-3Ј, phorbol 12-O-tetradecanoate-13-acetate-responsive element), is a homodimeric or heterodimeric leucine zipper complex containing the products of the fos and jun protooncogenes (45) . AP-1 has been identified as an intermediary in PDGF-induced proliferation of SMCs (34) . The activity of AP-1 is controlled not only by transcriptional and posttranscriptional mechanisms via increased rates of synthesis and decreased rates of degradation of fos and jun mRNA species, but also by translational and posttranslational (phosphorylation and redox regulation) mechanisms (7, 40, 45) (Fig. 6, lanes 7 and 8) , similar to results reported in response to heat shock in NIH 3T3 cells (8) . These findings suggest that PDGF-BB-induced DNA binding activity of AP-1 complex is dependent on redox regulation by Ref-1. AP-1 has been shown to downregulate the cyclin-dependent kinase inhibitor p21
Cip1/WAF1 (5a), induce cyclin D 1 (2) , and augment cyclin E expression (28) . Ref-1 may affect these cell cycle regulatory proteins by activating AP-1 activity, which in turn promotes G 0 /G 1 -S transition; future work will be necessary to examine the role of Ref-1 in regulation of these cell cycle proteins. We thank G. Hess and J. Fishbaugh for technical expertise in performing flow cytometric assays.
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